Video

Dr. Salles on Improving Immune Respone in Follicular Lymphoma

Gilles A. Salles, MD, PhD, Centre Hospitalier Lyon-Sud, discusses improving immune response in follicular lymphoma.

Gilles A. Salles, MD, PhD, Centre Hospitalier Lyon-Sud, discusses improving immune response in follicular lymphoma.

Agents such as lenalidomide (Revlimid) are being explored in the treatment landscape of follicular lymphoma to trigger immune responses in patients with follicular lymphoma. Anti—PD-1/PD-L1 agents may potentially be used to develop these responses as well, says Salles.

This is a step toward a rational understanding of how the immune system fights and can tackle lymphoma and, according to Salles, it may spare patients chemotherapy if effective.

Related Videos
Jonathan Spicer, MD, PhD, FRCS
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Binod Dhakal, MD
Sheldon M. Feldman, MD
Yair Lotan, MD, UT Southwestern Medical Center